Akero Therapeutics Current Valuation vs. Return On Asset
| AKRO Stock | USD 32.10 0.07 0.22% |
For Akero Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Akero Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Akero Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Akero Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Akero Therapeutics over time as well as its relative position and ranking within its peers.
Akero |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Akero Therapeutics Return On Asset vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Akero Therapeutics's current stock value. Our valuation model uses many indicators to compare Akero Therapeutics value to that of its competitors to determine the firm's financial worth. Akero Therapeutics is rated below average in current valuation category among its peers. It is rated below average in return on asset category among its peers . As of the 29th of November 2024, Return On Assets is likely to drop to -0.27. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Akero Therapeutics' earnings, one of the primary drivers of an investment's value.Akero Current Valuation vs. Competition
Akero Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 34.96 Billion. Akero Therapeutics holds roughly 1.56 Billion in current valuation claiming about 4% of equities under Health Care industry.
Akero Return On Asset vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Akero Therapeutics |
| = | 1.56 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Akero Therapeutics |
| = | -0.23 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Akero Return On Asset Comparison
Akero Therapeutics is currently under evaluation in return on asset category among its peers.
Akero Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Akero Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Akero Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Akero Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Akero Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 270 K | 283.5 K | |
| Operating Income | -172.9 M | -164.2 M | |
| Net Loss | -119.6 M | -125.6 M | |
| Income Before Tax | -151.8 M | -144.2 M | |
| Total Other Income Expense Net | 21.1 M | 22.2 M | |
| Net Loss | -100.8 M | -105.9 M | |
| Net Loss | -151.8 M | -144.2 M | |
| Income Tax Expense | -2.8 M | -2.7 M | |
| Interest Income | 24.2 M | 18.1 M | |
| Non Operating Income Net Other | 4.5 M | 4.7 M | |
| Net Interest Income | -2.6 M | -2.4 M | |
| Change To Netincome | 21.2 M | 25.8 M | |
| Net Loss | (2.89) | (3.03) | |
| Income Quality | 0.96 | 0.61 | |
| Net Income Per E B T | 1.12 | 1.09 |
Akero Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Akero Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Akero Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Akero Therapeutics' important profitability drivers and their relationship over time.
Use Akero Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Akero Therapeutics Pair Trading
Akero Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.
The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Akero Therapeutics position
In addition to having Akero Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Wireless Thematic Idea Now
Wireless
Companies providing wireless technology and communication services. The Wireless theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wireless Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
To fully project Akero Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Akero Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Akero Therapeutics' income statement, its balance sheet, and the statement of cash flows.